Payment overview · 2025
General Payments
$49.95
3 reported records · 3 companies
Healthcare provider profile · identity verified
Anthony J Branz, MD
Allopathic & Osteopathic Physicians|Family Medicine · OSBURN, ID · NPI 1700977170
Verified facts
What the public records show
CMS Open Payments records show Anthony J Branz, MD received $49.95 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.42 | 40.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.39 | 30.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.14 | 28.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.95 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 559 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 83 |
| Metformin Hcl | Metformin Hcl | 344 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 67 |
| Omeprazole | Omeprazole | 297 | 62 |
| Gabapentin | Gabapentin | 289 | 46 |
| Lisinopril | Lisinopril | 264 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 51 |
| Furosemide | Furosemide | 260 | 56 |
| Potassium Chloride | Potassium Chloride | 253 | 55 |
| Simvastatin | Simvastatin | 224 | 46 |
| Famotidine | Famotidine | 218 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 49 |
| Eliquis | Apixaban | 186 | 25 |
| Losartan Potassium | Losartan Potassium | 161 | 42 |
| Allopurinol | Allopurinol | 145 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 128 | 27 |
| Meloxicam | Meloxicam | 125 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 115 | 23 |
| Ozempic | Semaglutide | 114 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 113 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 25 |
| Bupropion Xl | Bupropion Hcl | 112 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 32 |
| Glimepiride | Glimepiride | 100 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 20 |
| Metformin Hcl Er | Metformin Hcl | 95 | 19 |
| Lorazepam | Lorazepam | 94 | 27 |
| Tramadol Hcl | Tramadol Hcl | 94 | 36 |
| Azithromycin | Azithromycin | 93 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 90 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 86 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 16 |
| Carvedilol | Carvedilol | 75 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 13 |
| Ezetimibe | Ezetimibe | 70 | 16 |
| Finasteride | Finasteride | 69 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 12 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 63 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 28 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 54 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 53 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Torsemide | Torsemide | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 52 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 50 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | 11 |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 16 |
| Warfarin Sodium | Warfarin Sodium | 45 | 11 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Telmisartan | Telmisartan | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 22 |
| Cefdinir | Cefdinir | 34 | 27 |
| Dilt-Xr | Diltiazem Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 23 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 15 |
| Dutasteride | Dutasteride | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 11 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Xifaxan | Rifaximin | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Renvela | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.95 · 3 records | ABBVIE INC. | FARXIGA, FREESTYLE LIBRE 3, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error